Treprostinil (L606) vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (L606)
Developed by Liquidia Corporation under a licence from Pharmosa Biopharm Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
NCT03399604 · Phase 3 · completed
The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
Reported efficacy
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)
Result source: NCT03399604
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Treprostinil (L606): no structured comparison results are available for Pulmonary Arterial Hypertension.
Available safety results
Treprostinil (Yutrepia, Liquidia)
| Dropout rate | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result24%LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
|---|---|
| Discontinued due to AEs | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Serious AEs | 12.4%LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Most frequent reported AEs | cough 33.9% headache 19% upper respiratory tract infection 14.9% NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (L606)'s landscape · Treprostinil (Yutrepia, Liquidia)'s landscape